Loading...

ImmunityBio, Inc.

IBRX•NASDAQ
Healthcare
Biotechnology
$7.44
$-0.75(-9.16%)
U.S. Market opens in 49h 27m

ImmunityBio, Inc. (IBRX) Stock Overview

Explore ImmunityBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7.6B
P/E Ratio-21.05
EPS (TTM)$-0.38
ROE0.64%
Fundamental Analysis

AI Price Forecasts

1 Month$8.52
3 Months$8.07
1 Year Target$3.04

IBRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmunityBio, Inc. (IBRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 46.85, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.04.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -21.05 and a market capitalization of 7.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-9.16%
5-Day Change
1.92%
1-Month Change
0.27%
3-Month Change
15.35%
6-Month Change
201.21%
Year-to-Date (YTD) Change
275.76%
1-Year Change
176.58%
3-Year Change
204.92%
5-Year Change
-60.88%
All-Time (Max) Change
-78.52%

Contact Information

https://immunitybio.com
858 633 0300
3530 John Hopkins Court, San Diego, CA, 92121

Company Facts

671 Employees
IPO DateJul 28, 2015
CountryUS
Actively Trading

Frequently Asked Questions